Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 2/20 | 0.49 |
| ▸ | GSTM2 | P28161 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 9/20 | 0.46 |
| ▸ | PPARA | Q07869 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | BCL2 | P10415 | 4/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27129942 | 1.00 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL29796768 | 0.95 | GSTP1 (0.46) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL26961654 | 0.90 | GSTP1 (0.50) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL27131730 | 0.89 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL20280135 | 0.89 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAALDH1A1 | |
| SCHEMBL26961765 | 0.89 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL29797181 | 0.89 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL28628373 | 0.89 | GSTP1 (0.49) | GSTP1GSTM2PPARGPPARAALDH1A1 | |
| SCHEMBL20280078 | 0.84 | PPARA (0.45) | GSTP1GSTM2PPARGPPARAKDM4E | |
| SCHEMBL27130964 | 0.84 | PPARA (0.45) | GSTP1GSTM2PPARGPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |
| CN-107889487-B | Bicyclic tetrahydrothiazepine derivatives for the treatment of tumor and/or infectious diseases | 阿派隆生物制剂股份公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| EP-3265463-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS AG (AT) | 2018-12-19 | — | — | EP | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
| EP-3265463-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | Apeiron Biologics AG (AT) | 2018-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | CCNT2, HRH4, HRH3 | GSTP1 4283/4885GSTM2 4138/4885PPARG 2349/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | GSTP1 4748/4885GSTM2 4763/4885PPARG 2445/4885 |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | CCNT2, HRH4, HRH3 | GSTP1 4283/4885GSTM2 4138/4885PPARG 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.